Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study long-term data achieves positive results.

Johnson & Johnson (JNJ.US) long-term data from two Phase 3 clinical trials showed that adult patients with Crohn's disease treated with Tremfya (guselkumab) achieved clinical remission rates of up to 94% within three years. According to the introduction, participants in the GALAXI 2 and GALAXI 3 trials first received Tremfya induction therapy, followed by maintenance therapy of 100 mg every eight weeks or 200 mg every four weeks, respectively. The remission rate was 94% in the eight-week regimen group and 91% in the four-week regimen group. In addition, 52% of patients in the eight-week regimen group achieved endoscopic remission, compared with 61% in the four-week regimen group. At the same time, 88% of patients in both groups achieved 90-day corticosteroid-free clinical remission. In addition, Johnson & Johnson stated that results from the Phase 3 FUZION study showed that Tremfya can achieve sustained fistula remission in a specific Crohn's disease subgroup. Overall, 28% of patients in the eight-week (q8w) regimen group and 27% of patients in the four-week (q4w) regimen group achieved the composite endpoint of comprehensive fistula remission at Week 24, compared with 10% in the placebo group. However, among patients with higher baseline luminal disease activity, the remission rates in the q8w and q4w groups were 30% and 21%, respectively, compared with 0% in the placebo group. Among patients who had previously received biologic therapy, as well as among patients with or without proctitis at baseline, fistula remission in those treated with Tremfya was also significantly better than in the placebo group.